Kumaska et al reported a case of a 43-year-old woman with MS and nephrotic syndrome 21 months after initiation of treatment with subcutaneous interferon (IFN)-β-1b for maintenance therapy.[16] She underwent a percutaneous renal biopsy, which revealed features of MCD and was subsequently placed on oral corticosteroid 2 weeks after cessation of IFN-β. Here, IFNB1 is linked to myeloid sarcoma.